Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
Go back to Theralase® Provides Update on Phase II Bladder Cancer Clinical Study| ISHARES 20+ YEAR TREASURY BOND ETF (NASDAQ: TLT) | Delayed: 83.44 -0.22 (0.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $83.66 | 52 Week High | $143.62 | |||
| Open | $83.61 | 52 Week Low | $118.66 | |||
| Day High | $83.70 | P/E | N/A | |||
| Day Low | $83.38 | EPS | $0.00 | |||
| Volume | 15,984,549 | |||||
| Theralase Technologies Inc Ordinary Share (AMEX: TLTFF) | Delayed: 0.19 +0.01 (5.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.18 | 52 Week High | $0.35 | |||
| Open | $0.19 | 52 Week Low | $0.18 | |||
| Day High | $0.19 | P/E | N/A | |||
| Day Low | $0.19 | EPS | $0.00 | |||
| Volume | 17,595 | |||||
